Table 2.
Pairwise meta-analytic results for attenuated psychotic symptoms at 6 and 12 months.
| Time point; months | Treatment condition | Control condition | Number of studies (references) | Total N | SMD (g) | Lower 95%CI | Upper 95%CI | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | Control | I2 | Q | P | |||||||
| 6 | ARI + NBI | NBI | 1 (24) | 96 | 55 | −0.22 | −0.56 | 0.11 | – | 0.00 | – |
| ARI + NBI | CBT-F+NBI | 1 (24) | 96 | 129 | −0.06 | −0.33 | 0.20 | – | 0.00 | – | |
| CBT-F + NBI | NBI | 5 (24, 29, 37, 74, 76) | 374 | 278 | −0.06 | −0.26 | 0.13 | 24.2 | 5.27 | 0.26 | |
| Dser + NBI | NBI | 1 (26) | 20 | 24 | −0.10 | −0.70 | 0.49 | – | 0.00 | – | |
| FFT + NBI | NBI | 1 (28) | 66 | 63 | −0.41 | −0.76 | −0.06 | – | 0.00 | – | |
| Om3 + NBI | NBI | 2 (27, 40) | 194 | 191 | −0.48 | −1.62 | 0.67 | 94.8 | 19.4 | <0.001 | |
| RIS + CBT-F + NBI | CBT-F+NBI | 1 (76) | 43 | 44 | 0.37 | −0.05 | 0.80 | – | 0.00 | – | |
| RIS + CBT-F + NBI | NBI | 2 (38, 76) | 74 | 56 | 0.02 | −0.33 | 0.37 | 0.00 | 0.72 | 0.40 | |
| ZIP + NBI | NBI | 1 (30) | 24 | 27 | −1.10 | −1.69 | −0.50 | – | 0.00 | – | |
| 12 | ARI + NBI | NBI | 1 (24) | 96 | 55 | −0.22 | −0.55 | 0.12 | – | 0.00 | – |
| ARI + NBI | CBT-F+NBI | 1 (24) | 96 | 129 | −0.08 | −0.34 | 0.18 | – | 0.00 | – | |
| CBT-F + NBI | NBI | 6 (24, 29, 37, 43, 74, 77) | 411 | 301 | −0.22 | −0.37 | −0.07 | 0.00 | 3.27 | 0.66 | |
| IPI | NBI | 1 (46) | 63 | 65 | 0.20 | −0.15 | 0.54 | – | 0.00 | – | |
| OLA + NBI | NBI | 1 (73) | 31 | 29 | −0.53 | −1.05 | −0.02 | – | 0.00 | – | |
| Om3 + NBI | NBI | 2 (27, 40) | 194 | 191 | −0.38 | −1.38 | 0.63 | 93.5 | 15.49 | <0.001 | |
| RIS + CBT-F + NBI | CBT-F+NBI | 1 (77) | 43 | 44 | −0.07 | −0.49 | 0.35 | – | 0.00 | – | |
| RIS + CBT-F + NBI | NBI | 2 (38, 77) | 74 | 56 | 0.00 | −0.38 | 0.38 | 16.2 | 1.19 | 0.28 | |
Underlined bold text within the SMD and 95% CI columns indicates statistically significant meta-analytic treatment effect. SMD below 0 favors the given treatment condition. ARI, aripiprazole; NBI, needs-based interventions (including placebo); CBT-F, cognitive behavioral therapy (French & Morrison protocol); Dser, D-serine; FFT, family-focused therapy; Om3, omega-3 fatty acids; RIS, risperidone; ZIP, ziprasidone; IPI, integrated psychological interventions; OLA, olanzapine. Dashes (–) indicate no heterogeneity estimate due to having only one contributing study (and thus cannot be considered a true meta-analytic result).